Through a secondary analysis of data from two former studies that involved 348 individuals with nonspecific low back pain, experts investigated the responsiveness of the Subgroups for Targeted Treatment at 6 weeks and 6 months. Most of the hypotheses were included. Examining the Subgroups for Targeted Treatment Back Screening Tool (SBST) as a consistent score, 85.7% and 87.5% of the hypotheses were taken into account at 6 weeks and 6 months, respectively. For medium- and high-risk subgroups, at 6 weeks and 6 months, 85.7% and 87.5% of the hypotheses were incorporated. The low-risk subgroup had 42.9% of the hypotheses considered at 6 weeks and 100% of the hypotheses acknowledged at 6 months. Therefore, in subgroups of individuals with a medium and high risk, high responsiveness of SBST at 6 weeks, and poor responsiveness in those with a low risk, of consistent disability was concluded. Furthermore, in all SBST subgroups at 6 months, the SBST has high responsiveness. Clinicians can assuredly utilize the SBST in terms of subgroups to estimate variations over time.